Latest Healthcare It News

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

PolyNovo Limited reports a robust FY25 with nearly 29% sales growth, a significant cash increase to A$33.5 million, and expanding global market presence. The company’s strategic investments and product innovations signal strong momentum ahead.

Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.

Centuria Capital No. 2 Fund confirms full compliance with note terms and stable loan positions in its Q4 FY25 report, reassuring investors amid a steady operational quarter.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

Radiopharm Theranostics reports significant progress in its oncology radiopharmaceutical pipeline, including FDA Fast Track designation and dose escalation approvals, supported by a solid cash runway through mid-2026.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.

Careteq Limited reports a significant reduction in operating cash outflow and modest revenue growth for FY25, while facing delays in its key platform integration and a dispute with the ATO over R&D claims.